CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
China's Road to Tackle Autoimmune Diseases Globally
Yesterday 08:00 AM
15 Chinese Companies to Watch in September 2022 – New Consumption
Oct 03, 2022 06:17 PM
China VC Investment List Q3 2022 - New Consumption
Oct 02, 2022 12:00 PM
15 Chinese Companies to Watch in August 2022 - Mobility
Sep 30, 2022 10:48 PM